Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.52 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.52 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.52 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3889085 | 0.93 | S1PR1 (0.50) | CACNA1BAPBA1SAE1UBA2S1PR1 | |
| SCHEMBL4176314 | 0.93 | S1PR1 (0.58) | S1PR1L3MBTL1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL3946565 | 0.92 | L3MBTL1 (0.48) | CACNA1BAPBA1SAE1UBA2S1PR1 | |
| SCHEMBL3948452 | 0.92 | KMT2A (0.53) | CACNA1BAPBA1SAE1UBA2S1PR1 | |
| SCHEMBL3948561 | 0.91 | S1PR1 (0.46) | CACNA1BAPBA1SAE1UBA2S1PR1 | |
| SCHEMBL4041962 | 0.91 | SMN1; SMN2 (0.51) | CACNA1BAPBA1SAE1UBA2S1PR1 | |
| SCHEMBL4045766 | 0.89 | SMN1; SMN2 (0.47) | CACNA1BAPBA1SAE1UBA2S1PR1 | |
| SCHEMBL4035723 | 0.89 | S1PR1 (0.46) | CACNA1BAPBA1SAE1UBA2S1PR1 | |
| SCHEMBL3944106 | 0.88 | KMT2A (0.53) | S1PR1RAB9ASMN1; SMN2MAPK1LMNA | |
| SCHEMBL3955854 | 0.87 | S1PR1 (0.46) | S1PR1MAPTALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | claimed |
| EP-2010511-A1 | CHROMEN-2-ONE DERIVATIVES | Novartis AG (CH) | 2009-01-07 | — | — | EP | claimed |
| WO-2007115820-A1 | CHROMEN-2-ONE DERIVATIVES | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | CYP1A2, CYP4B1, CYP1B1 | CACNA1B 4364/4885APBA1 3095/4885SAE1 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.